SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: EX-10.8
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/ex10-8.htm

Chunk 8 of 14
Word Count: 1410
Character Count: 8743

Document Content:

relevant mandatory provisions of EU law, the Relevant Parties. 3.3 Termination of Information. The covenants set forth in Section 3.1 and Section 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first; provided, that, with respect to clause (iii), the covenants set forth in Section 3.1 shall only terminate if the consideration received by the Investors in such Deemed Liquidation Event is in the form of cash and/or publicly traded securities or if the Investors receive financial information from the acquiring company or other successor to the Company comparable to those set forth in Section 3.1.

3.4 Confidentiality.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to
monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the Company
pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section
3.4 by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s
confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any
obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may
disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent
reasonably necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective
purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of
this Section 3.4; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of
such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is
confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by
law, regulation, rule, court order or subpoena, provided that such Investor promptly notifies the Company of such disclosure
and takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding the foregoing or anything to the
contrary contained in this Agreement, the Company acknowledges that the investments completed by Andera in the Company derive partly
from the European Investment Fund (“EIF”) through the ERF-EIF Facility and the Lfa-EIF Facility, and the Kreditanstalt
fuir Wiederaufbau (“KFW”) through the ERP Venture Capital Fondsfinanziering Facility. The Company further acknowledges
and agrees that (i) the EIF may publish on their website or produce press releases containing information related to the financing
provided pursuant to Andera’s investment in the Company, including the name and address of the EIF, Andera and the Company,
the purpose of the financing and the type and amount of financing received from Andera, and (ii) Andera may publish a press release
in connection with their respective investment in the Company, which will include an appropriate acknowledgement of the financial
support provided by the EIF with the backing of the European Union.

4.	Rights
to Future Stock Issuances .

4.1 Right
of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company proposes
to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled
to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself, (ii) its Affiliates
and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,”
as such term is defined in Rule 13d- 3 promulgated under the Exchange Act, of such Investor (“Investor Beneficial Owners”);
provided that each such Affiliate or Investor Beneficial Owner (x) is not a Competitor or FOIA Party, unless such party’s
purchase of New Securities is otherwise consented to by the Board of Directors, and (y) agrees to enter into this Agreement and each
of the Voting Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor”
under each such agreement (provided that any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor
under Sections 3.1 and 3.2 or as an Investor under 4.1 hereof).

(a) The
Company shall give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide intention to offer such
New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to
offer such New Securities.

notification to the Company within twenty (20) days after the Offer Notice is given, each Investor may elect to purchase or otherwise
acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion
that the Common Stock then held by such Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion
and/or exercise, as applicable, of the Series A Preferred Stock and any other Derivative Securities then held by such Investor) bears
to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Series A Preferred
Stock and any other Derivative Securities then outstanding). At the expiration of such twenty (20) day period, the Company shall promptly
notify each Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”)
of any other Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice,
each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares
specified above, up to that portion of the New Securities for which Investors were entitled to subscribe but that were not subscribed
for by the Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon
conversion and/or exercise, as applicable, of Series A Preferred Stock and any other Derivative Securities then held, by such Fully Exercising
Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable,
of the Series A Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase
such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of ninety (90)
days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c).

all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b),
the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and
sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more
favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the
New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right
provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors
in accordance with this Section 4.1.

(d) The
right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Certificate of
Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series A Preferred Stock in the Second
Tranche Closing (as defined in the Purchase Agreement) pursuant to the Purchase Agreement.